StockNews.AI
ANIP
StockNews.AI
182 days

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET

1. ANI Pharmaceuticals will release Q4 2024 results on February 28, 2025. 2. CEO and executives will discuss results on a conference call. 3. Focus on sustainable growth through Rare Disease and Generics business. 4. Conference is accessible via toll-free number and webcast.

3m saved
Insight
Article

FAQ

Why Bullish?

Positive earnings releases can enhance stock value. Past strong performance announcements boosted ANIP shares significantly.

How important is it?

Earnings report is crucial for investor sentiment around ANIP. It can directly affect short-term price movements.

Why Short Term?

Immediate market reaction expected post-earnings announcement. Historical patterns show quick price movements post-results.

Related Companies

ANIP
February 18, 2025 16:05 ET  | Source: ANI Pharmaceuticals, Inc. PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: Date Friday, February 28, 2025  Time8:00 a.m. ET  Toll free (U.S.) 800-579-2543  Conference ID4860276  Webcast (live and replay) www.anipharmaceuticals.com, under the “Investors” section   A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-756-0554 and entering access code 4860276. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Established Brands business. For more information, visit www.anipharmaceuticals.com. Investor Relations Contact:Lisa M. Wilson, In-Site Communications, Inc.212-452-2793lwilson@insitecony.com SOURCE: ANI Pharmaceuticals, Inc.

Related News